Murphy & Mullick Capital Management Corp Acquires New Shares in ICU Medical, Inc. (NASDAQ:ICUI)

Murphy & Mullick Capital Management Corp bought a new stake in ICU Medical, Inc. (NASDAQ:ICUI) during the fourth quarter, HoldingsChannel.com reports. The firm bought 337 shares of the medical instruments supplier’s stock, valued at approximately $52,000.

Several other institutional investors have also recently bought and sold shares of the business. Harvest Fund Management Co. Ltd acquired a new stake in shares of ICU Medical in the 4th quarter valued at approximately $33,000. Point72 Hong Kong Ltd bought a new position in ICU Medical in the 3rd quarter valued at approximately $72,000. Venturi Wealth Management LLC boosted its position in ICU Medical by 64.0% in the fourth quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier’s stock valued at $82,000 after buying an additional 206 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of ICU Medical by 166.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 907 shares of the medical instruments supplier’s stock worth $140,000 after buying an additional 567 shares during the last quarter. Finally, Coldstream Capital Management Inc. acquired a new position in shares of ICU Medical during the third quarter worth $227,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

ICU Medical Stock Performance

NASDAQ ICUI opened at $144.28 on Friday. The company has a market capitalization of $3.54 billion, a price-to-earnings ratio of -31.57 and a beta of 0.73. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a twelve month low of $93.36 and a twelve month high of $196.26. The stock has a fifty day simple moving average of $154.89 and a 200 day simple moving average of $164.01.

Insider Activity

In related news, CEO Vivek Jain sold 1,373 shares of ICU Medical stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total value of $213,474.04. Following the transaction, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at $16,262,119.64. The trade was a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.70% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective on the stock in a report on Wednesday, December 11th. Raymond James set a $97.00 price target on ICU Medical in a research note on Wednesday, March 12th. Finally, StockNews.com downgraded ICU Medical from a “buy” rating to a “hold” rating in a research note on Thursday. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $168.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.